Insmed – Biopharma company impresses with strong pipeline, EU approval for Brensocatib promises significant growth!

Business driver: Insmed (INS) specializes in the development of drugs and therapies for the treatment of rare lung and respiratory diseases. With ARIKAYCE (treatment for lung diseases caused by infection with human pathogenic atypical mycobacteria), Insmed already has an approved product, and due to potential expansion of indications, it sees peak revenue potential of $1 billion per year. Promising growth opportunities are primarily expected from the product Brensocatib, which has proven effective in clinical trials for the treatment of non-CF bronchiectasis,...